These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 20632895)

  • 21. Cost and effectiveness of cardiovascular prevention.
    Boyar A
    Am J Cardiol; 2007 Nov; 100(9):1492-4; author reply 1494-5. PubMed ID: 17950815
    [No Abstract]   [Full Text] [Related]  

  • 22. [Pharmacologic interventions in primary prevention: lipid lowering drugs, aspirin, antiobesity drugs, and antihypertensive agents].
    Auer J; Berent R; Weber T; Porodko M; Mayr H; Maurer E; Eber B
    Wien Med Wochenschr; 2001; 151(1-2):13-7. PubMed ID: 11234591
    [TBL] [Abstract][Full Text] [Related]  

  • 23. On reducing cardiovascular disease to a rarity: clinical strategies and their cost-effectiveness.
    Lewis B; Watts GF; Sullivan DR
    Heart Lung Circ; 2010 Apr; 19(4):225-7. PubMed ID: 20149730
    [No Abstract]   [Full Text] [Related]  

  • 24. The cost-effectiveness of drug treatments for primary prevention of cardiovascular disease: a modelling study.
    Marshall T
    Eur J Cardiovasc Prev Rehabil; 2006 Aug; 13(4):523-8. PubMed ID: 16874140
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Update on aspirin in the treatment and prevention of cardiovascular disease.
    Hennekens CH
    Am J Manag Care; 2002 Dec; 8(22 Suppl):S691-700. PubMed ID: 12512736
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aspirin for the primary prevention of adverse cardiovascular events.
    Estes K; Thomure J
    Crit Care Nurs Q; 2008; 31(4):324-39. PubMed ID: 18815480
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of antiplatelet therapy in a diabetic outpatient service of a large urban public hospital.
    Bruno A; Grassi G; Dani F; Degiovanni M; Maghenzani G; Pagano G
    Nutr Metab Cardiovasc Dis; 2005 Feb; 15(1):42-6. PubMed ID: 15871850
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aspirin for primary prevention of cardiovascular events in patients with diabetes: A meta-analysis.
    Zhang C; Sun A; Zhang P; Wu C; Zhang S; Fu M; Wang K; Zou Y; Ge J
    Diabetes Res Clin Pract; 2010 Feb; 87(2):211-8. PubMed ID: 19853947
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Aspirin in cardiovascular prevention: does the approach differ by gender?].
    Temizhan A
    Anadolu Kardiyol Derg; 2007 Dec; 7 Suppl 2():2-4. PubMed ID: 18160359
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The modern view on the use of aspirin for the primary prophylaxis of cardiovascular diseases in women].
    Zakharov OV; Arablinskiĭ AV
    Klin Med (Mosk); 2006; 84(11):10-5. PubMed ID: 17243603
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A model for undertaking effectiveness and cost-effectiveness analyses of primary preventive strategies in cardiovascular disease.
    Liew D; Lim SS; Bertram M; McNeil JJ; Vos T
    Eur J Cardiovasc Prev Rehabil; 2006 Aug; 13(4):515-22. PubMed ID: 16874139
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aspirin for the primary prevention of cardiovascular events: recommendations and rationale.
    U.S. Preventive Services Task Force
    Am J Nurs; 2002 Mar; 102(3):67, 69-70. PubMed ID: 11976531
    [No Abstract]   [Full Text] [Related]  

  • 33. An economic analysis of aspirin desensitization in aspirin-exacerbated respiratory disease.
    Shaker M; Lobb A; Jenkins P; O'Rourke D; Takemoto SK; Sheth S; Burroughs T; Dykewicz MS
    J Allergy Clin Immunol; 2008 Jan; 121(1):81-7. PubMed ID: 17716716
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Aspirin as primary prevention for diabetic patients].
    Fumeaux D; Becerra ME; Philippe J; Louis-Simonet M
    Rev Med Suisse; 2010 Feb; 6(234):244-8. PubMed ID: 20334083
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Meta-analysis of data from the six primary prevention trials of cardiovascular events using aspirin.
    Bartolucci AA; Howard G
    Am J Cardiol; 2006 Sep; 98(6):746-50. PubMed ID: 16950176
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Update for 1991. 6. Acetylsalicylic acid and the primary prevention of cardiovascular diseases. Canadian study group on the periodic medical examination].
    Union Med Can; 1993; 122(2):109-13. PubMed ID: 8493738
    [No Abstract]   [Full Text] [Related]  

  • 37. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women.
    Ridker PM; Cook NR; Lee IM; Gordon D; Gaziano JM; Manson JE; Hennekens CH; Buring JE
    N Engl J Med; 2005 Mar; 352(13):1293-304. PubMed ID: 15753114
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aspirin for primary prevention of cardiovascular events in people with diabetes.
    Pignone M; Alberts MJ; Colwell JA; Cushman M; Inzucchi SE; Mukherjee D; Rosenson RS; Williams CD; Wilson PW; Kirkman MS; ; ;
    J Am Coll Cardiol; 2010 Jun; 55(25):2878-86. PubMed ID: 20579547
    [No Abstract]   [Full Text] [Related]  

  • 39. Aspirin and angioplasty.
    Pentecost MJ
    J Am Coll Radiol; 2012 Feb; 9(2):95. PubMed ID: 22305694
    [No Abstract]   [Full Text] [Related]  

  • 40. Physician support for a population-based pharmaceutical approach to cardiovascular prevention: not there yet.
    Huy C; Litaker D
    Prev Med; 2011 Jan; 52(1):18-9. PubMed ID: 21130110
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.